Autonomix Medical (NASDAQ:AMIX) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of Autonomix Medical (NASDAQ:AMIX) from a sell rating to a strong sell rating in a research note released on Monday morning,Wall Street Zen reports.

Several other equities research analysts have also recently commented on AMIX. Zacks Research raised Autonomix Medical to a “hold” rating in a report on Tuesday, June 2nd. Weiss Ratings raised Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $42.00.

Autonomix Medical Stock Down 2.1%

AMIX stock opened at $4.12 on Monday. The company has a market capitalization of $4.00 million, a P/E ratio of -0.10 and a beta of -1.00. The company has a 50-day simple moving average of $5.78 and a 200 day simple moving average of $7.22. Autonomix Medical has a fifty-two week low of $2.44 and a fifty-two week high of $32.55.

Autonomix Medical (NASDAQ:AMIX) last released its earnings results on Wednesday, August 12th. The company reported ($5.02) EPS for the quarter, beating the consensus estimate of ($6.40) by $1.38. Equities analysts anticipate that Autonomix Medical will post -20.17 EPS for the current year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.